Clinical Trials Browser

Completed × Stomach Neoplasms × camrelizumab × Clear all

NCT03813784 2025-09-16

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Phase 3 Completed

Gastrointestinal

Stomach Neoplasms

NCT04510064 2025-03-12

Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT03878472 2024-12-16

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT04694183 2024-02-07

The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

Phase 2 Completed

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT03472365 2024-01-11

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Phase 2 Completed

67 enrolled 12 charts

Gastrointestinal

Stomach Neoplasms

NCT03755440 2022-09-21

PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms